Your session is about to expire
← Back to Search
Pembrolizumab for Ovarian Cancer
Study Summary
This trial looks at how effective pembrolizumab is in treating participants with cancer that has spread to other parts of the body. Monoclonal antibodies, like pembrolizumab, may prevent tumor cells from growing and spreading.
- Ovarian Cancer
- BRCA1 Mutation
- BRCA2 Mutation
- Solid Tumors
- Cancer
- POLD1 Mutation
- Gene Mutation
- Breast Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a mental health condition or substance abuse problem that may make it difficult for you to follow the study requirements.You are currently taking part in another study or have taken part in one within the last 4 weeks.You have a condition that weakens your immune system and require medications that suppress your immune system, or you have had life-threatening episodes related to your immune system even with current treatment.
- Group 1: Treatment (pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the U.S. Food and Drug Administration sanctioned Pembrolizumab?
"There is some evidence attesting to the safety of Pembrolizumab, leading it to receive a score of 2. This drug has yet to be proven efficacious in clinical trials."
Is this research endeavor actively seeking participants?
"Yes, clinicaltrials.gov records confirm that this trial is presently enrolling suitable applicants. It was initially published on March 8th 2018 and revised November 16th 2022. The research team requires 40 participants from 2 distinct sites."
What are the typical therapeutic applications of Pembrolizumab?
"Pembrolizumab is an effective remedy for combatting cancerous neoplasms. Additionally, this medicine can be prescribed to manage advanced melanoma, microsatellite instability high levels, and chemotherapy-induced deterioration of health."
What is the accepted participant quota for this medical investigation?
"Confirmed. Clinicaltrials.gov displays that the trial, which was first made available on March 8th 2018, is currently searching for participants. In total, 40 people are required to be recruited from two medical centres."
Are there any other trials that have utilized Pembrolizumab for research purposes?
"Research into Pembrolizumab is currently being conducted in 961 studies, and 122 of these are classified as Phase 3. Houston, Texas serves as the epicentre for many of the trials but there are a total 35731 locations across the globe where this drug can be tested."
Share this study with friends
Copy Link
Messenger